Almirall presents new lebrikizumab and tildrakizumab data at EADV 2026, including five-year atopic dermatitis and two-year psoriasis findings.
Written By: Anamika Koshti, PharmD
Reviewed By: Pharmacally Editorial Team
Almirall is presenting new clinical and real-world evidence for lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna from September 30 to October 3, 2026. The programme includes more than 20 abstracts across dermatology, with the two biologics representing the central focus of the company’s scientific programme.
Lebrikizumab: extending the evidence in atopic dermatitis
Lebrikizumab is a high-affinity, selective interleukin-13 (IL-13) inhibitor. At EADV 2026, Almirall is presenting data examining its efficacy and effectiveness across different body regions, patient populations and treatment settings, including difficult-to-treat areas such as the face, neck and hands.
The Phase 3b ADhope 1 study (NCT05990725) provides clinical evidence in adults and adolescents with moderate-to-severe AD. New analyses examine treatment outcomes in patients with involvement of the face, neck or hands, areas where AD can substantially affect daily life.
The European prospective observational ADtrust study (NCT06815380) and German real-world ADlife study extend the evidence into routine clinical practice. ADtrust provides 16-week interim patient-reported outcomes, while ADlife contributes real-world findings on skin symptoms, itch, disease control, flares and patient-reported outcomes. Together, these studies complement controlled clinical evidence with data from routine care.
Long-term durability is being assessed through ADjoin (NCT04392154), which follows patients from the ADvocate 1 and ADvocate 2 trials for up to three years.
The late-breaking ADlong Phase 3b extension study (NCT05916365) provides the longest follow-up in the programme. The new results report sustained improvements in skin signs and itch in patients with up to five years of lebrikizumab exposure. This extends earlier interim findings presented in March 2026, when Almirall reported sustained responses through four years of treatment.
Tildrakizumab: evaluating psoriasis beyond PASI
Tildrakizumab is an IL-23p19 inhibitor used in adults with moderate-to-severe plaque psoriasis. Almirall’s EADV programme examines not only skin clearance but also maintenance of disease control, patient well-being and outcomes in populations with greater treatment challenges.
A new post hoc analysis from the Phase 3 reSURFACE 1 trial (NCT01722331) evaluates the association between psoriasis duration and maintenance of disease control, defined as a PASI score of 2 or less, after tildrakizumab withdrawal. Because this is a post hoc analysis, the findings can generate hypotheses about earlier intervention and sustained control but cannot establish that earlier treatment causes better long-term outcomes.
The final two-year analyses from the POSITIVE study (NCT04823247) broaden the assessment beyond conventional measures of psoriasis severity. The study reports outcomes involving psychological well-being, quality of life, work productivity and treatment satisfaction, including patients with high-impact areas or burdensome symptoms.
Additional real-world evidence comes from PROCARE-T and PATH-T. The 28-week interim PROCARE-T data examine tildrakizumab effectiveness regardless of prior biologic exposure or disease duration, while PATH-T evaluates treatment outcomes in patients with high-impact-area psoriasis and previous biologic failure. These analyses provide additional evidence from patient populations that can present greater treatment challenges in routine practice.
What the EADV data show
Almirall’s EADV 2026 programme strengthens the evidence base for lebrikizumab and tildrakizumab across different dimensions of dermatology care. For lebrikizumab, the focus is on durability, difficult-to-treat body regions and real-world effectiveness, culminating in five-year ADlong data. For tildrakizumab, the programme expands the definition of treatment success to include sustained disease control, psychological well-being and outcomes in challenging patient populations.
The current announcement is a preview of congress presentations rather than a full publication of the underlying datasets. Several analyses are observational, interim or post hoc, and detailed efficacy and safety results should therefore be assessed against the individual EADV abstracts.
Almirall is also presenting separate evidence for tirbanibulin in actinic keratosis and CAL/BDP PAD cream in psoriasis, but these data are outside the main focus of this report.
Reference
Almirall advances skin science and shares new evidence across its dermatology portfolio at EADV 2026, Almirall, 30 September 2026
About the Writer
Anamika Koshti (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, and evidence-based medicine. She has authored peer-reviewed publications on Alzheimer’s disease and PCOS, presented research at national conferences, and gained hands-on experience in medical content development and clinical data interpretation. She is committed to translating complex medical research into accurate, accessible content for healthcare professionals and patients.